Showing results (1-10 of 137) with videos related to

Sort By:
Pageof 14
La Revue Du Praticien|June 25, 2013
[Treatment of multiple sclerosis: new approaches to treat case by case]Elisabeth Maillart, Caroline Papeix
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 7, 2025
Long-standing gadolinium enhancement in a patient with aquaporin-4-positive myelitisAliénor Jaillard, Elisabeth Maillart, Natalia Shor
Current Opinion in Neurology|March 18, 2024
Clinical characteristics of patients with myelin oligodendrocyte glycoprotein antibodiesElisabeth Maillart, Kumaran Deiva, Romain Marignier
BMJ Case Reports|August 29, 2012
Encephalitis and CSF increased level of interferon-α in Kikuchi-Fujimoto diseaseAntoine Guéguen, Thomas Sené, Elisabeth Maillart, et al.
Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement|October 31, 2017
Multiple sclerosis and agingCéline Louapre, Caroline Papeix, Catherine Lubetzki, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 25, 2013
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?Elisabeth Maillart, Céline Louapre, Catherine Lubetzki, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|June 14, 2017
Evaluation of French-language internet sites dealing with multiple sclerosisAntoine Guéguen, Elisabeth Maillart, Thibault Gallice, et al.
Multiple Sclerosis and Related Disorders|February 13, 2018
Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?Elisabeth Maillart, Anaïs Lippi, Catherine Lubetzki, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|May 28, 2023
Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up studyAnne-Charlotte Saponaro, Thomas Tully, Elisabeth Maillart, et al.
Multiple Sclerosis and Related Disorders|September 11, 2020
Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?Elisabeth Maillart, Caroline Papeix, Catherine Lubetzki, et al.
Pageof 14